@文章{info:doi/10.2196/27202，作者=“Ni, Zhao和Wu, Bei和Yang, Qing和Yan, Lijing L和Liu, Changqing和Shaw, Ryan J”，标题=“一种改善冠心病患者药物依从性和健康结局的移动健康干预:随机对照试验”，期刊=“J医学互联网研究”，年=“2022”，月=“3”，日=“9”，卷=“24”，数=“3”，页=“e27202”，关键词=“移动健康;药物治疗的依从性;冠状动脉疾病;血压;中国;背景:许多慢性疾病的治疗涉及长期的药物治疗，但找到有效的方法提高药物依从性以促进良好的健康结果是一个持续的挑战。心脏保护药物可以防止冠心病患者有害血栓、心血管症状和不良治疗结果的扩大，如无法控制的高血压和高脂血症。然而，据报道，冠心病患者对心脏保护药物的依从性差是一个全球性的健康问题，在中国尤其如此。目的:本研究旨在评估使用2个移动应用程序的移动健康(mHealth)干预的有效性，以改善药物依从性和健康结果。方法:在成都某大学附属医学中心进行随机、安慰剂对照、两臂平行研究。 Participants were recruited by flyers and health care provider referrals. Each participant was observed for 90 days, including a 60-day period of mHealth intervention and a 30-day period of nonintervention follow-up. The study coordinator used WeChat and Message Express to send educational materials and reminders to take medication, respectively. Participants used WeChat to receive both the educational materials and reminders. Participants in the control group only received educational materials. This study received ethics approval from the Duke Health Institutional Review Board (Pro00073395) on May 5, 2018, and was approved by West China Hospital (20170331180037). Recruitment began on May 20, 2018. The pilot phase of this study was registered on June 8, 2016, and the current, larger-scale study was retrospectively registered on January 11, 2021 (ClinicalTrials.gov). Results: We recruited 230 patients with coronary heart disease. Of these patients, 196 completed the baseline survey and received the intervention. The majority of participants were married (181/196, 92.4{\%}), male (157/196, 80.1{\%}), and lived in urban China (161/196, 82.1{\%}). Participants' average age was 61 years, and half were retired (103/191, 53.9{\%}). More than half the participants (121/196, 61.7{\%}) were prescribed at least 5 medications. The mean decrease in medication nonadherence score was statistically significant at both 60 days (t179=2.04, P=.04) and 90 days (t155=3.48, P<.001). Systolic blood pressure and diastolic blood pressure decreased in the experimental group but increased in the control group. The mean decrease in diastolic blood pressure was statistically significant at both 60 days (t160=2.07, P=.04) and 90 days (t164=2.21, P=.03). The mean decrease in systolic blood pressure was significantly different in the groups at 90 days (t165=3.12, P=.002). Conclusions: The proposed mHealth intervention can improve medication adherence and health outcomes, including systolic blood pressure and diastolic blood pressure. Trial Registration: ClinicalTrials.gov NCT02793830; https://clinicaltrials.gov/ct2/show/NCT02793830 and ClinicalTrials.gov NCT04703439; https://clinicaltrials.gov/ct2/show/NCT04703439 ", issn="1438-8871", doi="10.2196/27202", url="//www.mybigtv.com/2022/3/e27202", url="https://doi.org/10.2196/27202", url="http://www.ncbi.nlm.nih.gov/pubmed/35262490" }